- Home
- RDVT vs SAGE Comparison
RDVT vs SAGE Comparison
Compare RDVT & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDVT
- SAGE
- Stock Information
- Founded
- RDVT 2017
- SAGE 2010
- Country
- RDVT United States
- SAGE United States
- Employees
- RDVT N/A
- SAGE N/A
- Industry
- RDVT Computer Software: Prepackaged Software
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- RDVT Technology
- SAGE Health Care
- Exchange
- RDVT Nasdaq
- SAGE Nasdaq
- Market Cap
- RDVT 649.4M
- SAGE 571.1M
- IPO Year
- RDVT N/A
- SAGE 2014
- Fundamental
- Price
- RDVT $42.38
- SAGE $8.68
- Analyst Decision
- RDVT
- SAGE Hold
- Analyst Count
- RDVT 0
- SAGE 16
- Target Price
- RDVT N/A
- SAGE $9.37
- AVG Volume (30 Days)
- RDVT 79.6K
- SAGE 3.9M
- Earning Date
- RDVT 08-06-2025
- SAGE 07-30-2025
- Dividend Yield
- RDVT 0.70%
- SAGE N/A
- EPS Growth
- RDVT N/A
- SAGE N/A
- EPS
- RDVT 0.61
- SAGE N/A
- Revenue
- RDVT $79,681,000.00
- SAGE $70,411,000.00
- Revenue This Year
- RDVT $18.86
- SAGE $103.60
- Revenue Next Year
- RDVT $13.99
- SAGE $42.93
- P/E Ratio
- RDVT $70.23
- SAGE N/A
- Revenue Growth
- RDVT 26.30
- SAGE N/A
- 52 Week Low
- RDVT $3.03
- SAGE $4.62
- 52 Week High
- RDVT $52.24
- SAGE $11.44
- Technical
- Relative Strength Index (RSI)
- RDVT 31.85
- SAGE 46.60
- Support Level
- RDVT $44.08
- SAGE $8.71
- Resistance Level
- RDVT $45.32
- SAGE $8.82
- Average True Range (ATR)
- RDVT 1.24
- SAGE 0.07
- MACD
- RDVT -0.29
- SAGE -0.11
- Stochastic Oscillator
- RDVT 3.92
- SAGE 0.00
About RDVT Red Violet Inc.
Red Violet Inc is a software and services company. It specializes in data analysis, providing cloud-based, mission-critical information solutions to enterprises in a variety of industries. Through its CORE data fusion platform, it provides mission-critical information about individuals, businesses and assets.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.